RK-251 Cancer Drug

Why in News?

Scientists from various research institutions have developed a new “smart” cancer drug, RK-251, designed to become active primarily inside cancer cells while limiting damage to healthy cells. The approach could contribute to the development of more targeted cancer therapies and potentially reduce the adverse effects associated with conventional chemotherapy.

Key Points

RK-251 is designed to remain relatively inactive while circulating through the body and become activated when it encounters the distinctive biochemical environment of cancer cells.

Cancer cells often contain elevated levels of Reactive Oxygen Species (ROS) compared with normal cells. RK-251 exploits this difference as a biological trigger.

When RK-251 enters a cancer cell, the high ROS concentration triggers its activation and releases a potent anticancer compound called NBDHEX.

NBDHEX acts on target proteins that are involved in the survival and treatment resistance of cancer cells, thereby helping to inhibit their growth.

Why is it Significant?

Conventional chemotherapy can damage healthy cells along with cancer cells, resulting in adverse effects such as toxicity and other treatment-related complications.

The strategy behind RK-251 is based on selective activation, meaning that the drug is designed to become therapeutically active preferentially within cancer cells.

This represents a targeted-drug-delivery approach, in which the unique biochemical characteristics of tumour cells are used to activate the therapeutic agent.

CLICK HERE: UPSC PRELIMS & MAINS CURRENT AFFAIRS BASED WEEKLY TEST (ENG & HINDI)

CLICK HERE FOR GS TIMES PRAHAR UPSC GS MAINS TEST SERIES 

CLICK HERE: DAILY CURRENT AFFAIRS QUIZ (FOR ALL EXAMINATIONS)